Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TKT | P29401 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20722390 | 1.00 | SLC6A4 (0.34) | SLC6A4PDCD1LG2CD274LTA4HKCNH2 | |
| SCHEMBL30968452 | 1.00 | SLC6A4 (0.34) | SLC6A4PDCD1LG2CD274LTA4HKCNH2 | |
| SCHEMBL20722890 | 0.76 | USP2 (0.45) | — | |
| SCHEMBL20722892 | 0.76 | USP2 (0.45) | — | |
| SCHEMBL30968506 | 0.74 | KDM4E (0.40) | TKT | |
| SCHEMBL844810 | 0.74 | KDM4E (0.40) | TKT | |
| SCHEMBL31583261 | 0.71 | SCN4A (0.33) | PDCD1LG2CD274 | |
| SCHEMBL28586342 | 0.71 | PTGS2 (0.41) | PDCD1LG2CD274 | |
| SCHEMBL30060129 | 0.71 | PTGS2 (0.41) | PDCD1LG2CD274 | |
| SCHEMBL20732114 | 0.71 | PTGS2 (0.41) | PDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112867712-A | Carboxamides as ubiquitin-specific protease inhibitors | 瓦洛早期发现股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | SLC6A4 4571/4885PDCD1LG2 2775/4885CD274 4163/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | SLC6A4 4571/4885PDCD1LG2 2775/4885CD274 4163/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | SLC6A4 4571/4885PDCD1LG2 2775/4885CD274 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.